Larimar Therapeutics Inc
Company Profile
Business description
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Contact
Three Bala Plaza East
Suite 506
Bala CynwydPA19004
USAT: +1 844 511-9056
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
71
Stocks News & Analysis
stocks
Sales shine but broader macro outlook darkens for this ASX share
stocks
Chart of the Week: US equity market trading at an attractive discount
stocks
Undervalued ASX share retains wide moat rating despite regulatory pressures
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,168.90 | 43.80 | 0.48% |
| CAC 40 | 8,205.71 | 58.16 | -0.70% |
| DAX 40 | 23,744.10 | 336.53 | -1.40% |
| Dow JONES (US) | 47,769.34 | 140.58 | -0.29% |
| FTSE 100 | 10,583.05 | 25.83 | -0.24% |
| HKSE | 25,752.40 | 140.62 | -0.54% |
| NASDAQ | 22,595.00 | 39.99 | -0.18% |
| Nikkei 225 | 55,895.32 | 413.10 | -0.73% |
| NZX 50 Index | 13,273.81 | 19.87 | 0.15% |
| S&P 500 | 6,772.69 | 10.12 | -0.15% |
| S&P/ASX 200 | 8,973.20 | 57.80 | 0.65% |
| SSE Composite Index | 3,966.17 | 28.83 | -0.72% |